4 results about "Advanced cancer" patented technology

FIELD: anesthesiology; resuscitation.SUBSTANCE: following is determined before surgery: risk of surgery, presence of coronary heart disease, presence of cancer, presence of advanced cancer, and duration of voluntary threshold apnea in seconds. The risk of developing postoperative intestinal paresis is determined using an original formula.EFFECT: preoperative prediction of the development of intestinal paresis after abdominal surgery.1 cl, 2 tbl, 2 ex

The invention relates to medical uses of a compound of general formula (I), (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2, which can be the same group or a different group, are independently a hydroxy group or a methoxy group or, taken together, a methylenedioxy group, R3 and R4, which can be the same group or a different group, are independently a hydroxy group or a methoxy group, R5 is phenyl group, and R6 is a phenyl group, wherein said phenyl groups are independently optionally substituted, and wherein n is 2, and to pharmaceutical compositions comprising said compound of general formula (I), for use in the treatment of cancer in a human subject, wherein said compound of general formula (I) is administered in a therapeutically effective dose to said human subject. The invention is also related to medical uses of pharmaceutical compositions comprising said compound of general formula (I) or said pharmaceutically acceptable salt thereof.

This invention relates to the fields of medical data processing and multimodal emotion computing, and discloses an emotion state recognition system for vocal micro-expressions in patients with advanced cancer. The system constructs a temporal state vector reflecting the patient's neural control ability by calculating the neural conduction lag rate and the physiological vocal energy index. A state-adaptive gating module generates a confidence mask to weight the multimodal features. Subsequently, an emotion decoupling and reconstruction module uses manifold orthogonal projection to separate the weighted features into physiological harm perception components and psychological emotional response components, and combines sparse dictionary reconstruction to remove noise. Finally, a fusion decision and grading module combines a temporal convolutional network with an adaptive threshold calibration mechanism based on the energy index to output pain grading results and decision signals. This invention can effectively distinguish between a patient's subjective masking and physiological exhaustion state, decouple the physical and psychological attributes of pain, and avoid missed detections due to weak reactions.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.